Health Conditions: GLP-1 agonists: Medication may be better for those with type 2 diabetes or prediabetes, as they improve glycemic control and support weight loss
It is truncated analogue of growth hormone releasing hormone (GHRH), which was developed in 1980s from original GRF 1-29, but with purposefully prolonged half-life to ensure better therapeutical use
Trials are investigating whether these drugs can reduce risks of cardiovascular disease, fatty liver, and even dementia
The objective is not rapid acceleration, but improved metabolic consistency under structured care
Online sources offering unapproved GLP-1 medications often lack quality control, posing dangers of contamination, incorrect dosing, and unknown ingredients
Acute kidney injury due to volume depletion has been reported in postmarketing reports occurring in patients who experienced nausea, vomiting, or diarrhea, leading to dehydration